This week’s update looks at P-BCMA-ALLO1, a Cas-CLOVER-edited allogeneic CAR-T candidate that is being developed for the treatment of multiple...

Poseida Therapeutics' unique approach to gene editing and delivery addresses some of the major obstacles faced within cell and gene therapy...

This week we bring you a clinical trial update on GC027, a CRISPR-edited CAR T-cell therapy for relapsed or refractory CD7+ T cell acute lymphoblastic...

This week’s update looks at a Phase 1/2 study for ALLO-501A, a TALEN-edited CAR T-cell therapy for large B-cell lymphoma.

This week’s update looks at a CRISPR-edited CAR T-cell therapy in clinical development for the treatment of a range of B cell cancers.

This week’s update looks at a combined vaccine/CRISPR-edited T cell trial for prostate cancer, and a CRISPR-edited CAR-T cell trial for non-small cell...

In recent years, researchers have turned to gene editing to address the limitations of CAR T therapies. This roundup summarises the clinical-stage...

This week’s clinical update looks at 3 clinical trials for the treatment of sickle cell disease (SCD), relapsed or refractory blood cancers and...